Medicare To Reimburse Guardant Health’s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

CMS approves ADLT status for Guardant Health’s Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.

Latest Ratings for GH

DateFirmActionFromTo Feb 2022Wells FargoMaintainsOverweight Feb 2022Morgan StanleyMaintainsOverweight Feb 2022CitigroupMaintainsBuy

View More Analyst Ratings for GH

View the Latest Analyst Ratings

read more